Lv41
476 积分 2022-11-07 加入
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
1小时前
已完结
The evolution of the obesity drug market
1小时前
已完结
Breakthrough therapy designations in China and the United States
14天前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
18天前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
19天前
已完结
From gene hunter to drug hunter
1个月前
已完结
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Trends in the development of cellular and gene therapy in China
1个月前
已关闭
皖公网安备34019202002308
